The global smart pills market is projected to reach USD 1.30 billion by 2030 from USD 0.69 billion in 2024, at a CAGR of 11.2% during the forecast period. The key factors driving the market growth include technological advancements and innovative healthcare developments.
The pills are equipped with sensors, microprocessors, and wireless communication features and have revolutionized patient care through miniaturization, longer battery life, and improved data processing of pills for disease diagnosis. Furthermore, the pills meet critical healthcare needs by providing a non-invasive, convenient solution for tracking vital signs, ensuring medication adherence, and diagnosing gastrointestinal disorders. These pills enhance patient outcomes and reduce healthcare costs, signifying a significant advancement in modern medicine
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=840
Driver: Technological advancements in capsule endoscopy
Capsule endoscopy is a major advancement in the field of endoscopy and is rapidly replacing GI video scopes. Until the development of capsule endoscopy, the complete evaluation of the small bowel was complicated, making smart pills a disruptive technology that can revolutionize the diagnosis of small bowel diseases. Capsule endoscopy procedures are patient-friendly and provide a detailed view of the small bowel mucosa. The market has witnessed significant advancements in capsule endoscopy technology. Major developments and product approvals have been conducted in capsule propulsion, battery technology, and optics to provide the basis for future research and clinical studies.
Opportunity: Innovations in sensor technologies and wireless communication
Smart pills, equipped with sensors, microprocessors, and wireless communication features, have transformed the field of medicine. Innovations in miniaturization, extended battery life, and enhanced data processing capabilities have made these pills more efficient and accessible. Sensors have become smaller, lighter, and more efficient, allowing for their integration into pills that can be safely ingested. These miniature sensors can monitor physiological markers such as temperature, pressure, and pH levels in the body, which allows for continuous and real-time health data collection that was previously not possible. Modern sensors are now more sensitive and accurate than ever before, providing smart pills with more reliable data about a patient’s health, from disease monitoring to diagnosis.
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=840
Smart Pills Market, By Application
By application, smart pills market is bifurcated into capsule endoscopy, patient monitoring, and targeted drug delivery. In 2023, patient monitoring segment accounted for the second largest share of smart pills market. This is attributed to launch of innovative sensor technologies and the rising need for precise & accurate measurement of inner body temperatures. Increasing demand for streamlined integration is expected to enhance the adoption of smart pills due to expanded connectivity and compatibility with digital health systems
Smart Pills Market, By End Users
By end users, smart pills are divided into hospitals, diagnostic centers, outpatient settings (clinics, ambulatory care centers), and other end users. In 2023, the hospitals segment held the largest market share due to rising hospitalizations and surgical operations globally, poor medication adherence, and increasing demand for minimally invasive diagnostic monitoring devices. The non-invasive nature of smart pills, combined with their ability to enhance early detection & diagnosis, make them a lucrative substitute for hospitals seeking to advance patient care and address the growing burden of inflammatory bowel disease (IBD). According to the Chron’s and Colitis Foundation of America, as many as 70,000 new cases of inflammatory bowel disease (IBD) are diagnosed in the US annually. IBD, which includes Crohn’s disease and ulcerative colitis, affects roughly 1.6 million Americans, most of whom are diagnosed before age 35. Overall, the surge in IBD cases has prompted hospitals to embrace smart pills as a valuable tool in diagnostic procedures. The non-invasive nature of smart pills and their ability to enhance early detection and diagnosis makes them a lucrative alternative for hospitals seeking to improve patient care and address the increasing burden of IBD
The key players operating in the smart pills market include Medtronic (US), Olympus Corporation (Japan), CapsoVision,Inc. (US), IntroMedic (South Korea), ANX Robotics (US), Shenzhen Jifu Medical Technology Co., Ltd. (China), JINSHAN Science & Technology (Group) (China), etectrx (US), Check-Cap (Israel), BodyCap (France), and Shangxian Minimal Invasive Inc (China).
Enquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=840